Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives $187.72 Consensus PT from Analysts

Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report) has earned a consensus rating of “Moderate Buy” from the eighteen research firms that are currently covering the company, Marketbeat reports. Two analysts have rated the stock with a hold recommendation and sixteen have assigned a buy recommendation to the company. The average twelve-month price target among […]

Leave a Reply

Your email address will not be published.

Previous post Insider Buying: MultiPlan Co. (NYSE:MPLN) SVP Buys $25,161.15 in Stock
Next post Range Resources Co. (NYSE:RRC) Receives $37.30 Average PT from Brokerages